GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Goodbody Health Ltd (OTCPK:GDBYF) » Definitions » EV-to-EBITDA

Goodbody Health (Goodbody Health) EV-to-EBITDA : 2.66 (As of Apr. 27, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Goodbody Health EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Goodbody Health's enterprise value is $-3.67 Mil. Goodbody Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.38 Mil. Therefore, Goodbody Health's EV-to-EBITDA for today is 2.66.

The historical rank and industry rank for Goodbody Health's EV-to-EBITDA or its related term are showing as below:

GDBYF's EV-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 14.03
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), Goodbody Health's stock price is $0.0003. Goodbody Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.117. Therefore, Goodbody Health's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Goodbody Health EV-to-EBITDA Historical Data

The historical data trend for Goodbody Health's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goodbody Health EV-to-EBITDA Chart

Goodbody Health Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Dec21
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -6.61 -0.84 -542.15

Goodbody Health Quarterly Data
Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.57 -542.15 7.00 -719.49 -1.50

Competitive Comparison of Goodbody Health's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Goodbody Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Goodbody Health's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Goodbody Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Goodbody Health's EV-to-EBITDA falls into.



Goodbody Health EV-to-EBITDA Calculation

Goodbody Health's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-3.666/-1.377
=2.66

Goodbody Health's current Enterprise Value is $-3.67 Mil.
Goodbody Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Goodbody Health  (OTCPK:GDBYF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Goodbody Health's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0003/-0.117
=At Loss

Goodbody Health's share price for today is $0.0003.
Goodbody Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.117.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Goodbody Health EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Goodbody Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Goodbody Health (Goodbody Health) Business Description

Traded in Other Exchanges
N/A
Address
Stubbs Lane, Beckington Frome, The Blue Building, Somerset, GBR, BA11 6TE
Goodbody Health Ltd is a wellness company operating in both COVID testing in the United Kingdom and as a vertically integrated cannabinoid CBD company that operates in the United Kingdom and the European Union. It has interests in COVID testing clinics, CBD extraction, wholesale bulk isolate, and distillate sales, retail CBD and white label sales, cannabinoid laboratory testing, and medicinal cannabis research programs.